CRISPR Therapeutics Hires Tony Ho From AstraZeneca to Lead R&D

Frank Vinluan

Frank Vinluan

August 4th, 2017

Xconomy Boston —

CRISPR Therapeutics (NASDAQ: CRSP) has hired Tony Ho to serve as the company’s executive vice president and head of research and development. Switzerland-based CRISPR Therapeutics, which maintains its R&D operations in Cambridge, MA, is developing therapies based on the CRISPR gene-editing technology. Ho comes to the company from AstraZeneca (NYSE: AZN), where he was senior vice president and head of oncology integration and innovation.

Frank Vinluan is editor of Xconomy Raleigh-Durham, based in Research Triangle Park. You can reach him at fvinluan [at] xconomy.com Follow @frankvinluan

Trending on Xconomy

Underwriters and Partners

Xpertise: Watch + Learn

Sponsored · Whitepaper
Protecting Your Life Science Manufacturing Operations: Monitoring Solutions
Implementing a reliable and auditable monitoring program for life science samples, assets & equipment
XiltriX

Sponsored · Whitepaper
Monitoring Solutions for Pharma-CRO/CMO Partnerships to Maintain Quality & Timelines
Implementing electronic solutions for risk mitigation
XiltriX

Sponsored · Whitepaper
Protecting Valuable Life Science Assets & Equipment: Monitoring Solutions
Remain compliant and ensure optimal productivity
XiltriX

Tweets from https://twitter.com/Xconomy/lists/lifesci